Antiphospholipid Syndrome (APS)
0
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Allergy TherapeuticsUK - West Sussex
1 programPilot Study of Gut Commensals in Antiphospholipid SyndromeN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Chugai PharmaRAY121
Chugai PharmaRAY121
Allergy TherapeuticsPilot Study of Gut Commensals in Antiphospholipid Syndrome
Clinical Trials (3)
Total enrollment: 304 patients across 3 trials
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
Start: Dec 2024Est. completion: Apr 2027144 patients
Phase 1Enrolling By Invitation
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Start: Aug 2024Est. completion: Jun 2026144 patients
Phase 1Recruiting
Pilot Study of Gut Commensals in Antiphospholipid Syndrome
Start: Feb 2013Est. completion: Dec 202616 patients
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 304 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.